Skip to main content

Table 1 Eligibility criteria

From: Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial

Inclusion criteria Exclusion criteria
Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate) Is HIV positive
Is aged of 18–65 years old Is concomitant with mental disorders
Is previously untreated or treated less than 1 month with anti-TB drugs Is concomitant with diabetes while mellitus blood glucose out of control
Has 2 positive sputum smear results for mycobacterium TB at screening Is pregnant or breastfeeding
Has a chest X-ray abnormality compatible with a diagnosis of PTB Has a prolonged QTcFa (>480 ms)
Is not pregnant for female patient at bearing age and willing to use effective contraception during study period Is currently participate in another trial of a medicinal product
Has CrClb > 30 ml/ min, HBc > 7.0 g/dL and PLTd > 50 × 109/L at screening Is concomitant with severe cardiovascular, hepatic, renal, nervous system, hematopoietic system injury and other diseases, or concomitant with neoplastic diseases
Has ALTe and TBILf less than 2 times the upper limit of normal at screening Has extensive lesion in the lung concomitant with respiratory insufficiency
  Has known allergy to any of the anti-TB drugs in the trial
  Is taking any medications contraindicated with the medicines in any trial regimen of the study
  1. a QTcF Fridericia-corrected QT, b CrCl creatinine clearance, c HB hemoglobin, d PLT Platelet, e ALT alanine aminotransferase, f TBIL total bilirubin